Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
Colin S Tan,1,2 SriniVas R Sadda3 1National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; 2Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore; 3Doheny Eye Institute, University of California Los Angeles, CA, USA Abstract: Myopic choroidal neovascul...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-09-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/anti-vascular-endothelial-growth-factor-therapy-for-the-treatment-of-m-peer-reviewed-article-OPTH |
| _version_ | 1818684620475990016 |
|---|---|
| author | Tan CS Sadda SR |
| author_facet | Tan CS Sadda SR |
| author_sort | Tan CS |
| collection | DOAJ |
| description | Colin S Tan,1,2 SriniVas R Sadda3 1National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; 2Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore; 3Doheny Eye Institute, University of California Los Angeles, CA, USA Abstract: Myopic choroidal neovascularization (CNV) is a sight-threatening condition which occurs in eyes with myopia, particularly in those with pathologic myopia. It is the most common cause of CNV among patients younger than 50 years. Hemorrhage and exudation from the CNV lesion may eventually result in scarring or chorioretinal atrophy. While myopic CNV was previously treated with focal laser photocoagulation or photodynamic therapy (PDT), the current treatment of choice is anti-vascular endothelial growth factor (VEGF) agents. Many studies have demonstrated the efficacy of intravitreal anti-VEGF agents in the treatment of myopic CNV. The RADIANCE study reported that intravitreal ranibizumab was superior to PDT in eyes with myopic CNV (at 3 months, both groups receiving intravitreal ranibizumab gained 10.5 and 10.6 letters vs 2.2 letters among patients receiving PDT). In addition, the study demonstrated similar visual outcomes in eyes treated on the basis of visual acuity stabilization or disease activity criteria. Other clinical studies have provided evidence for the efficacy of ranibizumab and aflibercept in the treatment of myopic CNV. This review addresses the epidemiology, pathophysiology, and imaging characteristics of myopic CNV, and discusses the evidence for the efficacy of anti-VEGF agents as compared to laser photocoagulation and PDT. Keywords: myopic choroidal neovascularization, ranibizumab, anti-vascular endothelial growth factor |
| first_indexed | 2024-12-17T10:53:32Z |
| format | Article |
| id | doaj.art-93f14c634ca5426ba9dd5b7e646b0f42 |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-12-17T10:53:32Z |
| publishDate | 2017-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-93f14c634ca5426ba9dd5b7e646b0f422022-12-21T21:51:54ZengDove Medical PressClinical Ophthalmology1177-54832017-09-01Volume 111741174634896Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularizationTan CSSadda SRColin S Tan,1,2 SriniVas R Sadda3 1National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; 2Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore; 3Doheny Eye Institute, University of California Los Angeles, CA, USA Abstract: Myopic choroidal neovascularization (CNV) is a sight-threatening condition which occurs in eyes with myopia, particularly in those with pathologic myopia. It is the most common cause of CNV among patients younger than 50 years. Hemorrhage and exudation from the CNV lesion may eventually result in scarring or chorioretinal atrophy. While myopic CNV was previously treated with focal laser photocoagulation or photodynamic therapy (PDT), the current treatment of choice is anti-vascular endothelial growth factor (VEGF) agents. Many studies have demonstrated the efficacy of intravitreal anti-VEGF agents in the treatment of myopic CNV. The RADIANCE study reported that intravitreal ranibizumab was superior to PDT in eyes with myopic CNV (at 3 months, both groups receiving intravitreal ranibizumab gained 10.5 and 10.6 letters vs 2.2 letters among patients receiving PDT). In addition, the study demonstrated similar visual outcomes in eyes treated on the basis of visual acuity stabilization or disease activity criteria. Other clinical studies have provided evidence for the efficacy of ranibizumab and aflibercept in the treatment of myopic CNV. This review addresses the epidemiology, pathophysiology, and imaging characteristics of myopic CNV, and discusses the evidence for the efficacy of anti-VEGF agents as compared to laser photocoagulation and PDT. Keywords: myopic choroidal neovascularization, ranibizumab, anti-vascular endothelial growth factorhttps://www.dovepress.com/anti-vascular-endothelial-growth-factor-therapy-for-the-treatment-of-m-peer-reviewed-article-OPTHMyopic choroidal neovascularizationranibizumabanti-vascular endothelial growth factor |
| spellingShingle | Tan CS Sadda SR Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization Clinical Ophthalmology Myopic choroidal neovascularization ranibizumab anti-vascular endothelial growth factor |
| title | Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization |
| title_full | Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization |
| title_fullStr | Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization |
| title_full_unstemmed | Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization |
| title_short | Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization |
| title_sort | anti vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization |
| topic | Myopic choroidal neovascularization ranibizumab anti-vascular endothelial growth factor |
| url | https://www.dovepress.com/anti-vascular-endothelial-growth-factor-therapy-for-the-treatment-of-m-peer-reviewed-article-OPTH |
| work_keys_str_mv | AT tancs antivascularendothelialgrowthfactortherapyforthetreatmentofmyopicchoroidalneovascularization AT saddasr antivascularendothelialgrowthfactortherapyforthetreatmentofmyopicchoroidalneovascularization |